FAS REREGISTERED THE FIRST PRICE FOR A REFERENCE MEDICINE

FAS forwarded a decision on approving the maximum ex-work price for a Hungarian-made medicine - bromocriptine - to the Ministry of Healthcare of the Russian Federation

Although the procedure for mandatory re-registration of the maximum ex-works prices for vital and essential medicinal medicine (VED) [1] came into force relatively recently – on 17 December 2019, the antimonopoly authority has already launched robust efforts to execute the instructions of the Government of Russia.

“FAS has successfully agreed upon the first price for a reference medicine - bromocriptine, which is listed as a vital and essential drug. The decision оn approval was published on the official web-site of the Antimonopoly Service and is forwarded to the Ministry of Healthcare of the Russian Federation. FAS expects that all manufacturers on the Russian pharmaceutical market should be actively involved in reviewing prices for medicine, which will allow us to adjust them in accord with the prices on medicine in the reference countries”, says Timophei Nizhegorodtsev, Head of FAS Department for Control over Social Sphere and Trade.

Manufacturers must file applications for mandatory registration of prices for original (reference) medicines to the Ministry of Healthcare of the Russian Federation by 18 February 2020. Reviewed ceiling ex-works prices for medicine come into effect five months after a relevant order of the Russian Ministry of Healthcare is issued.

Reviewing prices for medicines listed as vital and essential medicine must be completed by the end of 2020.

Background:

[1] № 1683 Decree of the Government of the Russian Federation of 16.12.2019.